EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update

Josef S Smolen, Christopher J Edwards, Victoria Konzett, Faidra Laskou, Daniel Aletaha, Roberto Caporali, Thomas Dörner, Kimme L Hyrich, Elsa Mateus, Janet E Pope, Jette Primdahl, Savia de Souza und 38 weitere

Annals of the Rheumatic Diseases · 2026-06 · 85 (6) · 991-1009

DOI: 10.1016/j.ard.2026.01.023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026-06. Verfasst von Josef S Smolen und 49 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria. Electronic address: josef.smolen@meduniwien.ac.at. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Biological Products, Synthetic Drugs. Die Arbeit wurde bisher 112-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Alliance of Associations for Rheumatology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aims to provide an update of the European Alliance of Associations for Rheumatology (EULAR) rheumatoid arthritis (RA) management recommendations addressing the most recent insights. METHODS: An International Task Force was formed with a wide expertise and solicited 2 systemic literature research activities on the safety and efficacy of disease-modifying antirheumatic drugs (DMARDs). New evidence was discussed, considering the update from 2022. A voting process was applied to each item. Levels of evidence and strengths of recommendation were assigned, and participants voted on the levels of agreement. RESULTS: The task force agreed on 5 overarching principles and reduced the number of recommendations to 9 concerning use of conventional synthetic DMARDs (methotrexate [MTX], leflunomide, sulfasalazine); glucocorticoids (GCs); biological (b)DMARDs (tumour necrosis factor inhibitors [adalimumab, certolizumab pegol, etanercept, golimumab, infliximab], abatacept, rituximab, tocilizumab, sarilumab, including biosimilars) and targeted synthetic [ts]DMARDs (namely the Janus kinase inhibitors [JAKi] tofacitinib, baricitinib, filgotinib, upadacitinib). Guidance on monotherapy, combination therapy, treatment strategies (treat-to-target), and tapering following clinical remission is provided. Safety aspects, including risk of major cardiovascular events (MACEs) and malignancies, costs and sequencing of b/tsDMARDs were considered. Initially, MTX ideally in combination with short-term GCs is recommended; upon insufficient response after 3 to 6 months, a bDMARD should be added; after careful consideration of risks, including MACEs, malignancies and/or thrombo-embolic events, JAKi may also be considered. If the first bDMARD (or JAKi) fails, any other bDMARD (from another or the same class) or JAKi (considering risks) is recommended. With sustained remission, DMARDs may be tapered, but caution is required as stopping often leads to a flare. Levels of evidence and levels of agreement were high for most recommendations. CONCLUSIONS: These updated EULAR recommendations provide consensus on RA management based on currently available evidence regarding efficacy, safety, and cost.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidBiological ProductsSynthetic DrugsHumansDrug Therapy, CombinationGlucocorticoids

Substanzen

Antirheumatic AgentsBiological ProductsGlucocorticoidsSynthetic Drugs

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria. Electronic address: josef.smolen@meduniwien.ac.at.
  • NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.
  • MRC Lifecourse Epidemiology Centre, Southampton, UK.
  • Department of Clinical Science and Community Health, University of Milan, Milan, Italy; Department of Rheumatology and Medical Sciences, ASST Pini-CTO, Milan, Italy.
  • Department of Medicine/Rheumatology and Clinical Immunology, Charite Universitätsmedizin Berlin & Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany.

Förderung

  • European Alliance of Associations for Rheumatology

Zitieren

APA

Smolen, J. S., Edwards, C. J., Konzett, V., Laskou, F., Aletaha, D., Caporali, R., Dörner, T., Hyrich, K. L., Mateus, E., Pope, J. E., Primdahl, J., de Souza, S., Stamm, T., Takeuchi, T., van der Heijde, D., Verschueren, P., Winthrop, K. L., Alvaro-Gracia, J. M., Askling, J., …, & Landewé, R. B. M. (2026). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Annals of the Rheumatic Diseases, 85(6), 991-1009. https://doi.org/10.1016/j.ard.2026.01.023

Vancouver

Smolen JS, Edwards CJ, Konzett V, Laskou F, Aletaha D, Caporali R, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Annals of the Rheumatic Diseases. 2026;85(6):991-1009. doi:10.1016/j.ard.2026.01.023

BibTeX
@article{Smolen2026,
  author = {Smolen, Josef S and Edwards, Christopher J and Konzett, Victoria and Laskou, Faidra and Aletaha, Daniel and Caporali, Roberto and Dörner, Thomas and Hyrich, Kimme L and Mateus, Elsa and Pope, Janet E and Primdahl, Jette and de Souza, Savia and Stamm, Tanja and Takeuchi, Tsutomu and van der Heijde, Désirée and Verschueren, Patrick and Winthrop, Kevin L and Alvaro-Gracia, Jose Maria and Askling, Johan and Bathon, Joan and Buch, Maya H and Burmester, Gerd R and Codreanu, Catalin and Conaghan, Philip G and Cutolo, Maurizio and Fautrel, Bruno and Fonseca, Joao and Gossec, Laure and Haavardsholm, Espen and Hetland, Merete Lund and Iagnocco, Annamaria and Juge, Pierre-Antonie and Li, Zhanguo and Moe, Rikke Helene and Nash, Peter and Poór, Gyula and Rubbert-Roth, Andrea and Sobrin, Raquel Dos Santos and Schulze-Koops, Hendrik and Shumnalieva, Russka and Senolt, Ladislav and Silva-Fernandez, Lucia and Strangfeld, Anja and Taylor, Peter and Turesson, Carl and van Duuren, Elsa and de Wit, Maarten and Xavier, Ricardo and Kerschbaumer, Andreas and Landewé, Robert B M},
  title = {EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  volume = {85},
  number = {6},
  pages = {991--1009},
  doi = {10.1016/j.ard.2026.01.023}
}
Kostenlos starten →